Z K Wszolek

List of Publications by Year in Descending Order

303 papers	18,380 citations	60 h-index	129 g-index
327 ext. papers	21,619 ext. citations	6.7 avg, IF	6.06 L-index

#	Paper	IF	Citations
303	Neuropathological Findings of CSF1R-Related Leukoencephalopathy After Long-Term Immunosuppressive Therapy.. *Movement Disorders*, **2022**,	7	0
302	Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis.. *JAMA Neurology*, **2022**,	17.2	3
301	Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model.. *Frontiers in Cell and Developmental Biology*, **2022**, 10, 863089	5.7	0
300	Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges.. *Cellular and Molecular Life Sciences*, **2022**, 79, 219	10.3	2
299	Poly (ADP-Ribose) and □synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity.. *PLoS ONE*, **2022**, 17, e0264446	3.7	0
298	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders.. *Cell Reports Medicine*, **2022**, 3, 100607	18	0
297	Editor□ Thank You to Our Authors and Reviewers.. *Neurologia I Neurochirurgia Polska*, **2022**, 56, 115-117	1	
296	Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood.. *Movement Disorders*, **2022**, 37, 1120-1121	7	
295	Reply to "Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R-Related Leukoencephalopathy".. *Movement Disorders*, **2022**, 37, 1109-1110	7	
294	Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development.. *Frontiers in Neurology*, **2021**, 12, 788168	4.1	1
293	Neuropathology of McLeod Syndrome.. *Movement Disorders*, **2021**,	7	1
292	Professor Jaros□w S□wek elected Secretary of the International Association of Parkinsonism and Related Disorders. *Neurologia I Neurochirurgia Polska*, **2021**, 55, 415	1	
291	Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples. *Autophagy*, **2021**, 17, 2613-2628	10.2	12
290	Investigating ELOVL7 coding variants in multiple system atrophy. *Neuroscience Letters*, **2021**, 749, 135723	3.3	1
289	Editors of the Polish Journal of Neurology and Neurosurgery announce the first issue featuring a Leading Topic. *Neurologia I Neurochirurgia Polska*, **2021**, 55, 119	1	
288	Frequency of mutations in PRKN, PINK1, and DJ1 in Patients With Early-Onset Parkinson Disease from neighboring countries in Central Europe. *Parkinsonism and Related Disorders*, **2021**, 86, 48-51	3.6	0
287	Genomewide Association Studies of LRRK2 Modifiers of Parkinson□ Disease. *Annals of Neurology*, **2021**, 90, 76-88	9.4	9

286	Editorial Board meeting of the Polish Journal of Neurology and Neurosurgery - announcement of the gold open access for the journal. *Neurologia I Neurochirurgia Polska*, **2021**, 55, 237-238	1	
285	Genetics of Parkinson disease in the Polish population. *Neurologia I Neurochirurgia Polska*, **2021**, 55, 241-252	1	2
284	Reply to: "Investigation of Disease Modifying Mechanisms in CSF1R-Related Leukoencephalopathy". *Movement Disorders*, **2021**, 36, 1471	7	1
283	First Polish case of CSF1R-related leukoencephalopathy. *Neurologia I Neurochirurgia Polska*, **2021**, 55, 239-240	1	2
282	Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. *Science Translational Medicine*, **2021**, 13,	17.5	16
281	Frequency of spinocerebellar ataxia mutations in patients with multiple system atrophy. *Clinical Autonomic Research*, **2021**, 31, 117-125	4.3	2
280	Is Pre-Symptomatic Immunosuppression Protective in CSF1R-Related Leukoencephalopathy?. *Movement Disorders*, **2021**, 36, 852-856	7	9
279	Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson disease. *Parkinsonism and Related Disorders*, **2021**, 83, 22-30	3.6	2
278	Association of Mitochondrial DNA Genomic Variation With Risk of Pick Disease. *Neurology*, **2021**, 96, e1755-e1760	6.5	
277	Latent trait modeling of tau neuropathology in progressive supranuclear palsy. *Acta Neuropathologica*, **2021**, 141, 667-680	14.3	2
276	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nature Genetics*, **2021**, 53, 294-303	36.3	31
275	The AD tau core spontaneously self-assembles and recruits full-length tau to filaments. *Cell Reports* , **2021**, 34, 108843	10.6	8
274	Treatment of CSF1R-Related Leukoencephalopathy: Breaking New Ground. *Movement Disorders*, **2021**,	7	8
273	Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3. *Parkinsonism and Related Disorders*, **2021**, 89, 151-154	3.6	3
272	Clinical, pathological and genetic characteristics of Perry disease-new cases and literature review. *European Journal of Neurology*, **2021**, 28, 4010-4021	6	2
271	Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank. *Parkinsonism and Related Disorders*, **2021**, 89, 155-161	3.6	5
270	Apolipoprotein E regulates lipid metabolism and -synuclein pathology in human iPSC-derived cerebral organoids. *Acta Neuropathologica*, **2021**, 142, 807-825	14.3	2
269	Latest bibliometric factors for the Polish Journal of Neurology and Neurosurgery. *Neurologia I Neurochirurgia Polska*, **2021**, 55, 329-330	1	

268	-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. *Science Translational Medicine*, **2021**, 13, eabc9375	17.5	6
267	Screening of GBA Mutations in Nigerian Patients with Parkinson Disease. *Movement Disorders*, **2021**,	7	0
266	Neuropathology of progressive supranuclear palsy after treatment with tilavonemab. *Lancet Neurology, The*, **2021**, 20, 786-787	24.1	2
265	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. *Acta Neuropathologica Communications*, **2020**, 8, 218	7.3	4
264	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. *JAMA Network Open*, **2020**, 3, e2022847	10.4	5
263	Genetic characterization of Parkinson disease patients in Ecuador and Colombia. *Parkinsonism and Related Disorders*, **2020**, 75, 27-29	3.6	2
262	Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy. *Acta Neuropathologica Communications*, **2020**, 8, 72	7.3	20
261	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. *Neurology*, **2020**, 95, e35-e45	6.5	3
260	Subtypes of dementia with Lewy bodies are associated with -synuclein and tau distribution. *Neurology*, **2020**, 95, e155-e165	6.5	18
259	Crohn and Parkinson Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14 Blood Monocytes Ex Vivo. *Journal of NeuroImmune Pharmacology*, **2020**, 15, 794-800	6.9	7
258	Prevalence of GBA p.K198E mutation in Colombian and Hispanic populations. *Parkinsonism and Related Disorders*, **2020**, 73, 16-18	3.6	2
257	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. *Neurobiology of Aging*, **2020**, 88, 42-50	5.6	9
256	Bioethics and informatics in medical studies during the coronavirus disease 2019 pandemic. *Polish Archives of Internal Medicine*, **2020**, 130, 719	1.9	
255	What can Parkinson disease teach us about COVID-19?. *Neurologia I Neurochirurgia Polska*, **2020**, 54, 204-206	1	13
254	Spinocerebellar ataxia type 6 family with phenotypic overlap with Multiple System Atrophy. *Neurologia I Neurochirurgia Polska*, **2020**, 54, 350-355	1	2
253	A practical approach to adult-onset white matter diseases, with illustrative cases. *Neurologia I Neurochirurgia Polska*, **2020**, 54, 312-322	1	1
252	Response to "Does amantadine have a protective effect against COVID-19?". *Neurologia I Neurochirurgia Polska*, **2020**, 54, 286-287	1	1
251	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurology, The*, **2020**, 19, 145-156	24.1	90

250	Comment on: "The Geographic Diversity of Spinocerebellar Ataxias (SCAs) in the Americas: A Systematic Review". *Movement Disorders Clinical Practice*, **2020**, 7, 237-238	2.2	1
249	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. *Science Translational Medicine*, **2020**, 12,	17.5	15
248	Association of mitochondrial genomic background with risk of Multiple System Atrophy. *Parkinsonism and Related Disorders*, **2020**, 81, 200-204	3.6	0
247	Plasma neurofilament light predicts mortality in patients with stroke. *Science Translational Medicine* , **2020**, 12,	17.5	20
246	Microglial replacement therapy: a potential therapeutic strategy for incurable CSF1R-related leukoencephalopathy. *Acta Neuropathologica Communications*, **2020**, 8, 217	7.3	14
245	Association of MAPT subhaplotypes with clinical and demographic features in Parkinson's disease. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1557-1563	5.3	2
244	Cognitive and behavioral profile of Perry syndrome in two families. *Parkinsonism and Related Disorders*, **2020**, 77, 114-120	3.6	2
243	GBA variation and susceptibility to multiple system atrophy. *Parkinsonism and Related Disorders*, **2020**, 77, 64-69	3.6	6
242	APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. *Nature Communications*, **2020**, 11, 5540	17.4	59
241	Letter to the editor, "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease". *Parkinsonism and Related Disorders*, **2020**, 79, 130	3.6	
240	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. *Acta Neuropathologica Communications*, **2020**, 8, 172	7.3	3
239	Screening non-MAPT genes of the Chr17q21 H1 haplotype in Parkinson's disease. *Parkinsonism and Related Disorders*, **2020**, 78, 138-144	3.6	3
238	Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures. *Acta Neuropathologica Communications*, **2020**, 8, 162	7.3	6
237	Early-Onset Parkinson Disease Screening in Patients From Nigeria. *Frontiers in Neurology*, **2020**, 11, 594927	4.1	1
236	Perry syndrome: a case of atypical parkinsonism with confirmed DCTN1 mutation: a response. *New Zealand Medical Journal*, **2020**, 133, 84-85	0.8	1
235	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. *Movement Disorders*, **2019**, 34, 1655-1662	7	8
234	Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension. *Neurology*, **2019**, 93, e1339-e1347	6.5	7
233	Miro1 Marks Parkinson's Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinson's Models. *Cell Metabolism*, **2019**, 30, 1131-1140.e7	24.6	49

232	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. *Acta Neuropathologica*, **2019**, 138, 237-250	14.3	50
231	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. *Journal of Neuroimaging*, **2019**, 29, 624-629	2.8	6
230	Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. *JAMA Neurology*, **2019**, 76, 710-717	17.2	23
229	A proteomic signature for dementia with Lewy bodies. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 270-276	5.2	13
228	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. *Acta Neuropathologica*, **2019**, 137, 879-899	14.3	50
227	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. *Alzheimer's and Dementia*, **2019**, 15, 1218-1228	1.2	20
226	Rates of lobar atrophy in asymptomatic mutation carriers. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 338-346	6	13
225	Frontal lobe H MR spectroscopy in asymptomatic and symptomatic mutation carriers. *Neurology*, **2019**, 93, e758-e765	6.5	10
224	A patient clinically diagnosed as multiple system atrophy harboring p.G2019S. *Clinical Parkinsonism & Related Disorders*, **2019**, 1, 100-101	0.9	1
223	No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease. *Neurobiology of Aging*, **2019**, 74, 236.e1-236.e5	5.6	1
222	Partial loss of function of colony-stimulating factor 1 receptor in a patient with white matter abnormalities. *European Journal of Neurology*, **2018**, 25, 875-881	6	7
221	Anticipation in a family with primary familial brain calcification caused by an SLC20A2 variant. *Neurologia I Neurochirurgia Polska*, **2018**, 52, 386-389	1	3
220	PINK1 Phosphorylates MIC60/Mitofilin to Control Structural Plasticity of Mitochondrial Crista Junctions. *Molecular Cell*, **2018**, 69, 744-756.e6	17.6	58
219	Daytime sleepiness in dementia with Lewy bodies is associated with neuronal depletion of the nucleus basalis of Meynert. *Parkinsonism and Related Disorders*, **2018**, 50, 99-103	3.6	12
218	Multiple system atrophy and apolipoprotein E. *Movement Disorders*, **2018**, 33, 647-650	7	11
217	Comparison of clinical features among Parkinson's disease subtypes: A large retrospective study in a single center. *Journal of the Neurological Sciences*, **2018**, 386, 39-45	3.2	24
216	Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. *Alzheimer's Research and Therapy*, **2018**, 10, 2	9	20
215	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 548-558	24.1	60

214	Diaphragmatic Pacemaker for Perry Syndrome. *Mayo Clinic Proceedings*, **2018**, 93, 263	6.4	7
213	Diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia due to CSF1R mutation. *European Journal of Neurology*, **2018**, 25, 142-147	6	38
212	Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. *Molecular Neurodegeneration*, **2018**, 13, 37	19	28
211	4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. *Neurology*, **2018**, 91, e1182-e1195	6.5	77
210	Identification and functional characterization of novel mutations including frameshift mutation in exon 4 of CSF1R in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. *Journal of Neurology*, **2018**, 265, 2415-2424	5.5	14
209	Diffuse Lewy body disease manifesting as corticobasal syndrome: A rare form of Lewy body disease. *Neurology*, **2018**, 91, e268-e279	6.5	30
208	Establishing diagnostic criteria for Perry syndrome. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 482-487	5.5	26
207	The limbic and neocortical contribution of synuclein, tau, and amyloid to disease duration in dementia with Lewy bodies. *Alzheimers and Dementia*, **2018**, 14, 330-339	1.2	40
206	Atypical parkinsonian syndromes: a general neurologist perspective. *European Journal of Neurology*, **2018**, 25, 41-58	6	27
205	Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons. *American Journal of Human Genetics*, **2018**, 103, 874-892	11	15
204	Association study between multiple system atrophy and TREM2 p.R47H. *Neurology: Genetics*, **2018**, 4, e257	3.8	5
203	-related leukoencephalopathy: A major player in primary microgliopathies. *Neurology*, **2018**, 91, 1092-1104	6.5	61
202	APOE 2 is associated with increased tau pathology in primary tauopathy. *Nature Communications*, **2018**, 9, 4388	17.4	68
201	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. *Molecular Neurodegeneration*, **2018**, 13, 53	19	41
200	TRIO gene segregation in a family with cerebellar ataxia. *Neurologia I Neurochirurgia Polska*, **2018**, 52, 743-749	1	5
199	The PINK1 p.I368N Mutation Affects Protein Stability and Kinase Activity with Its Structural Change. *Juntendo Medical Journal*, **2018**, 64, 17-30	0.1	
198	Whole-exome sequencing for variant discovery in blepharospasm. *Molecular Genetics & Genomic Medicine*, **2018**, 6, 601	2.3	15
197	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. *Autophagy*, **2018**, 14, 1404-1418	10.2	47

196	Occurrence of Crohn disease with Parkinson disease. *Parkinsonism and Related Disorders*, **2017**, 37, 116-117	3.6	22
195	APOE 4/4 diminishes neurotrophic function of human iPSC-derived astrocytes. *Human Molecular Genetics*, **2017**, 26, 2690-2700	5.6	107
194	The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. *Molecular Neurodegeneration*, **2017**, 12, 32	19	37
193	DCTN1-related neurodegeneration: Perry syndrome and beyond. *Parkinsonism and Related Disorders*, **2017**, 41, 14-24	3.6	37
192	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. *Brain*, **2017**, 140, e33	11.2	2
191	Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. *Movement Disorders*, **2017**, 32, 246-255	7	34
190	Spinocerebellar ataxia 15: A phenotypic review and expansion. *Neurologia I Neurochirurgia Polska*, **2017**, 51, 86-91	1	7
189	Cognitive impairment in progressive supranuclear palsy is associated with tau burden. *Movement Disorders*, **2017**, 32, 1772-1779	7	30
188	Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. *Human Molecular Genetics*, **2017**, 26, 4861-4872	5.6	61
187	Frontotemporal Dementia **2017**, 115-125		
186	Brain calcification in a CSF1R mutation carrier precedes white matter degeneration. *Movement Disorders*, **2017**, 32, 1493-1495	7	3
185	DCTN1 variation in pathologically-confirmed PSP and CBD tauopathy. *Parkinsonism and Related Disorders*, **2017**, 44, 151-153	3.6	3
184	Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy. *Parkinsonism and Related Disorders*, **2017**, 42, 85-89	3.6	8
183	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. *Neuron*, **2017**, 95, 808-816.e9	13.9	341
182	Perry Syndrome: A Distinctive Type of TDP-43 Proteinopathy. *Journal of Neuropathology and Experimental Neurology*, **2017**, 76, 676-682	3.1	29
181	Heterozygous PINK1 p.G411S increases risk of Parkinson disease via a dominant-negative mechanism. *Brain*, **2017**, 140, 98-117	11.2	88
180	Profile of cognitive impairment and underlying pathology in multiple system atrophy. *Movement Disorders*, **2017**, 32, 405-413	7	68
179	Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. *Movement Disorders*, **2017**, 32, 115-123	7	34

178	FTDP-17 with Pick body-like inclusions associated with a novel tau mutation, p.E372G. *Brain Pathology*, **2017**, 27, 612-626	6	11
177	Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation. *European Journal of Neurology*, **2017**, 24, 37-45	6	74
176	Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy. *Neuropathology and Applied Neurobiology*, **2017**, 43, 200-214	5.2	37
175	Diagnostic Value of Brain Calcifications in Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia. *American Journal of Neuroradiology*, **2017**, 38, 77-83	4.4	37
174	Autosomal dominant Parkinson's disease caused by SNCA duplications. *Parkinsonism and Related Disorders*, **2016**, 22 Suppl 1, S1-6	3.6	100
173	Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. *JAMA Neurology*, **2016**, 73, 1217-1224	17.2	120
172	Cancer in Parkinson's disease. *Parkinsonism and Related Disorders*, **2016**, 31, 28-33	3.6	27
171	Cerebral peduncle angle: Unreliable in differentiating progressive supranuclear palsy from other neurodegenerative diseases. *Parkinsonism and Related Disorders*, **2016**, 32, 31-35	3.6	4
170	LRRK2 variation and dementia with Lewy bodies. *Parkinsonism and Related Disorders*, **2016**, 31, 98-103	3.6	21
169	Identification of genetic modifiers of age-at-onset for familial Parkinson's disease. *Human Molecular Genetics*, **2016**, 25, 3849-3862	5.6	37
168	Genome-wide association study in essential tremor identifies three new loci. *Brain*, **2016**, 139, 3163-3169	11.2	57
167	Rare variants in MC1R/TUBB3 exon 1 are not associated with Parkinson's disease. *Annals of Neurology*, **2016**, 79, 331	9.4	7
166	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. *Alzheimer's and Dementia*, **2016**, 12, 1297-1304	1.2	21
165	Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms. *Parkinsonism and Related Disorders*, **2016**, 22, 102-5	3.6	12
164	Assessment of Olfactory Function in MAPT-Associated Neurodegenerative Disease Reveals Odor-Identification Irreproducibility as a Non-Disease-Specific, General Characteristic of Olfactory Dysfunction. *PLoS ONE*, **2016**, 11, e0165112	3.7	9
163	Novel radiology method for investigating middle ear myoclonus. *Clinical Anatomy*, **2016**, 29, 811-2	2.5	1
162	Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSP-C. *Movement Disorders*, **2016**, 31, 653-62	7	43
161	MAPT haplotype diversity in multiple system atrophy. *Parkinsonism and Related Disorders*, **2016**, 30, 40-5	3.6	18

160	RAB39B gene mutations are not a common cause of Parkinson disease or dementia with Lewy bodies. *Neurobiology of Aging*, **2016**, 45, 107-108	5.6	18
159	Tremor in progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2016**, 27, 93-7	3.6	14
158	Hypertrophic olivary degeneration: A clinico-radiologic study. *Parkinsonism and Related Disorders*, **2016**, 28, 36-40	3.6	32
157	Deep brain stimulation for levodopa-refractory benign tremulous parkinsonism. *Neurologia I Neurochirurgia Polska*, **2016**, 50, 383-6	1	1
156	Primary familial brain calcification in the [illegible]BGC2[illegible]kindred: All linkage roads lead to SLC20A2. *Movement Disorders*, **2016**, 31, 1901-1904	7	13
155	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. *Neurology: Genetics*, **2016**, 2, e85	3.8	15
154	Genetics of Parkinson disease: a review of SNCA and LRRK2. *Wiadomo[illegible]i Lekarskie*, **2016**, 69, 328-32	0.3	6
153	Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1. *Mayo Clinic Proceedings*, **2015**, 90, 366-71	6.4	10
152	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. *Nature Communications*, **2015**, 6, 7247	17.4	118
151	When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. *Neurology*, **2015**, 85, 404-12	6.3	182
150	TREM2 R47H variant and risk of essential tremor: a cross-sectional international multicenter study. *Parkinsonism and Related Disorders*, **2015**, 21, 306-9	3.6	26
149	Role for the microtubule-associated protein tau variant p.A152T in risk of [illegible]synucleinopathies. *Neurology*, **2015**, 85, 1680-6	6.5	23
148	VPS35 and DNAJC13 disease-causing variants in essential tremor. *European Journal of Human Genetics*, **2015**, 23, 887-8	5.3	20
147	(Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation. *EMBO Reports*, **2015**, 16, 1114-30	6.5	102
146	Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. *Molecular Neurodegeneration*, **2015**, 10, 46	19	47
145	DNAJC13 p.Asn855Ser mutation screening in Parkinson disease and pathologically confirmed Lewy body disease patients. *European Journal of Neurology*, **2015**, 22, 1323-5	6	15
144	CHCHD2 and Parkinson disease. *Lancet Neurology, The*, **2015**, 14, 679	24.1	15
143	Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. *Neurology*, **2015**, 85, 2016-25	6.5	40

142	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. *Acta Neuropathologica*, **2015**, 130, 877-89	14.3	176
141	Three sib-pairs of autopsy-confirmed progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2015**, 21, 101-5	3.6	29
140	PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. *Neurology*, **2015**, 84, 972-80	6.5	38
139	Clinical presentation of a patient with SLC20A2 and THAP1 deletions: differential diagnosis of oromandibular dystonia. *Parkinsonism and Related Disorders*, **2015**, 21, 329-31	3.6	4
138	Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinson's Disease Locus. *PLoS ONE*, **2015**, 10, e0128586	3.7	
137	Latin America's first case of Perry syndrome and a new treatment option for respiratory insufficiency. *Journal of Neurology*, **2014**, 261, 620-1	5.5	9
136	Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. *Cell*, **2014**, 157, 472-485	56.2	182
135	SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. *Neurogenetics*, **2014**, 15, 23-30	3	49
134	Genetic screening and functional characterization of PDGFRB mutations associated with basal ganglia calcification of unknown etiology. *Human Mutation*, **2014**, 35, 964-71	4.7	37
133	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. *Neurobiology of Aging*, **2014**, 35, 2421.e13-7	5.6	62
132	Update on novel familial forms of Parkinson's disease and multiple system atrophy. *Parkinsonism and Related Disorders*, **2014**, 20 Suppl 1, S29-34	3.6	56
131	Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study. *Parkinsonism and Related Disorders*, **2014**, 20, 1274-8	3.6	25
130	A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study. *Parkinsonism and Related Disorders*, **2014**, 20, 1129-34	3.6	6
129	Parkinsonian syndrome in familial frontotemporal dementia. *Parkinsonism and Related Disorders*, **2014**, 20, 957-64	3.6	62
128	Three families with Perry syndrome from distinct parts of the world. *Parkinsonism and Related Disorders*, **2014**, 20, 884-8	3.6	19
127	Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson's disease. *Neurobiology of Aging*, **2014**, 35, 1958.e1-2	5.6	18
126	ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. *Molecular Neurodegeneration*, **2014**, 9, 11	19	33
125	Analysis of nuclear export sequence regions of FUS-Related RNA-binding proteins in essential tremor. *PLoS ONE*, **2014**, 9, e111989	3.7	8

124	LRRK2 exonic variants and risk of multiple system atrophy. *Neurology*, **2014**, 83, 2256-61	6.5	34
123	A rare sequence variant in intron 1 of THAP1 is associated with primary dystonia. *Molecular Genetics & Genomic Medicine*, **2014**, 2, 261-72	2.3	18
122	In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. *Movement Disorders*, **2014**, 29, 1197-201	7	12
121	DCTN1 mutations and progressive supranuclear palsy-like phenotype. *JAMA Neurology*, **2014**, 71, 655	17.2	2
120	Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. *Human Molecular Genetics*, **2014**, 23, 3157-65	5.6	31
119	Agraphia in patients with frontotemporal dementia and parkinsonism linked to chromosome 17 with P301L MAPT mutation: dysexecutive, aphasic, apraxic or spatial phenomenon?. *Neurocase*, **2014**, 20, 69-86	0.8	13
118	SLC1A2 rs3794087 does not associate with essential tremor. *Neurobiology of Aging*, **2014**, 35, 935.e9-10	5.6	14
117	Investigating FUS variation in Parkinson□ disease. *Parkinsonism and Related Disorders*, **2014**, 20 Suppl 1, S147-9	3.6	6
116	Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. *Acta Neuropathologica*, **2014**, 127, 271-82	14.3	60
115	Autosomal dominant cerebellar ataxia type III: a review of the phenotypic and genotypic characteristics. *Orphanet Journal of Rare Diseases*, **2013**, 8, 14	4.2	21
114	Novel A18T and pA29S substitutions in □synuclein may be associated with sporadic Parkinson□ disease. *Parkinsonism and Related Disorders*, **2013**, 19, 1057-1060	3.6	51
113	Analysis of the C9orf72 repeat in Parkinson□ disease, essential tremor and restless legs syndrome. *Parkinsonism and Related Disorders*, **2013**, 19, 198-201	3.6	35
112	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. *Parkinsonism and Related Disorders*, **2013**, 19, 869-77	3.6	45
111	TARDBP mutations in Parkinson□ disease. *Parkinsonism and Related Disorders*, **2013**, 19, 312-5	3.6	31
110	An adult-onset leukoencephalopathy with axonal spheroids and pigmented glia accompanied by brain calcifications: a case report and a literature review of brain calcifications disorders. *Journal of Neurology*, **2013**, 260, 2665-8	5.5	15
109	Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy. *Neurology*, **2013**, 80, 2076-8	6.5	23
108	CSF1R mutations link POLD and HDLS as a single disease entity. *Neurology*, **2013**, 80, 1033-40	6.5	108
107	Diversity of pathological features other than Lewy bodies in familial Parkinson□ disease due to SNCA mutations. *American Journal of Neurodegenerative Disease*, **2013**, 2, 266-75	2.5	19

106	Autosomal dominant Parkinson disease. *Parkinsonism and Related Disorders*, **2012**, 18 Suppl 1, S7-10	3.6	35
105	A novel de novo pathogenic mutation in the CACNA1A gene. *Movement Disorders*, **2012**, 27, 1578-9	7	2
104	Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): a misdiagnosed disease entity. *Journal of the Neurological Sciences*, **2012**, 314, 130-7	3.2	60
103	MRI characteristics and scoring in HDLS due to CSF1R gene mutations. *Neurology*, **2012**, 79, 566-74	6.5	68
102	Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson disease. *Science Translational Medicine*, **2012**, 4, 141ra90	17.5	381
101	Atypical motor and behavioral presentations of Alzheimer disease: a case-based approach. *Neurologist*, **2012**, 18, 266-72	1.6	26
100	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. *Brain*, **2012**, 135, 765-83	11.2	277
99	Update on genetics of parkinsonism. *Neurodegenerative Diseases*, **2012**, 10, 257-60	2.3	22
98	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nature Genetics*, **2011**, 43, 699-705	36.3	386
97	Ataxin-2 repeat-length variation and neurodegeneration. *Human Molecular Genetics*, **2011**, 20, 3207-12	5.6	128
96	Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron*, **2011**, 72, 245-56	13.9	3267
95	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. *Acta Neuropathologica*, **2011**, 122, 673-90	14.3	245
94	Clinical aspects of familial forms of frontotemporal dementia associated with parkinsonism. *Journal of Molecular Neuroscience*, **2011**, 45, 359-65	3.3	14
93	Autosomal dominant cerebellar ataxia type I: a review of the phenotypic and genotypic characteristics. *Orphanet Journal of Rare Diseases*, **2011**, 6, 33	4.2	40
92	Anatomy of disturbed sleep in pallido-ponto-nigral degeneration. *Annals of Neurology*, **2011**, 69, 1014-1025	9.4	10
91	MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. *Neurology*, **2011**, 76, 670-2	6.5	59
90	Diagnosis and treatment of common forms of tremor. *Seminars in Neurology*, **2011**, 31, 65-77	3.2	77
89	A family with Parkinsonism, essential tremor, restless legs syndrome, and depression. *Neurology*, **2011**, 76, 1623-30	6.5	25

88	Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. *Nature Genetics*, **2011**, 44, 200-5	36.3	344
87	Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. *Neurodegenerative Diseases*, **2010**, 7, 175-9	2.3	108
86	Frontotemporal Dementia. *Blue Books of Neurology*, **2010**, 34, 397-416		
85	Elucidating the genetics and pathology of Perry syndrome. *Journal of the Neurological Sciences*, **2010**, 289, 149-54	3.2	35
84	In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. *Parkinsonism and Related Disorders*, **2010**, 16, 404-8	3.6	59
83	LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. *Neurogenetics*, **2010**, 11, 401-8	3	106
82	Clinical implications of gene discovery in Parkinson disease and parkinsonism. *Movement Disorders* , **2010**, 25 Suppl 1, S15-20	7	14
81	Genetics of Parkinson disease and essential tremor. *Current Opinion in Neurology*, **2010**, 23, 388-93	7.1	27
80	Characterization of DCTN1 genetic variability in neurodegeneration. *Neurology*, **2009**, 72, 2024-8	6.5	44
79	Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD): a single entity?. *Neurology*, **2009**, 72, 1953-9	6.5	84
78	Corticobasal syndrome with Alzheimer disease pathology. *Movement Disorders*, **2009**, 24, 152-3; author reply 153	7	15
77	Brainstem atrophy on routine MR study in pallidopontonigral degeneration. *Journal of Neurology*, **2009**, 256, 827-9	5.5	5
76	Familial idiopathic basal ganglia calcification: a challenging clinical-pathological correlation. *Journal of Neurology*, **2009**, 256, 839-42	5.5	33
75	DCTN1 mutations in Perry syndrome. *Nature Genetics*, **2009**, 41, 163-5	36.3	239
74	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. *European Journal of Neurology*, **2009**, 16, 297-309	6	143
73	Pallidonigral TDP-43 pathology in Perry syndrome. *Parkinsonism and Related Disorders*, **2009**, 15, 281-6	3.6	72
72	Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. *Parkinsonism and Related Disorders*, **2009**, 15, 300-6	3.6	78
71	Clinical features of LRRK2 parkinsonism. *Parkinsonism and Related Disorders*, **2009**, 15 Suppl 3, S205-8	3.6	47

70	Clinical and Genetic Description of a Family With a High Prevalence of Autosomal Dominant Restless Legs Syndrome. *Mayo Clinic Proceedings*, **2009**, 84, 134-138	6.4	21
69	Clinical and genetic description of a family with a high prevalence of autosomal dominant restless legs syndrome. *Mayo Clinic Proceedings*, **2009**, 84, 134-8	6.4	5
68	Rapidly progressive familial parkinsonism with central hypoventilation, depression and weight loss (Perry syndrome)--a literature review. *Parkinsonism and Related Disorders*, **2008**, 14, 1-7	3.6	50
67	Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids. *Neurology*, **2008**, 71, 925-9	6.5	47
66	Are Parkinson disease patients protected from some but not all cancers?. *Neurology*, **2008**, 71, 1650; author reply 1650-1	6.5	13
65	Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. *Neurology*, **2008**, 71, 1790-5	6.5	95
64	Neurodegeneration involving putative respiratory neurons in Perry syndrome. *Acta Neuropathologica*, **2008**, 115, 263-8	14.3	46
63	Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson disease. Variability in familial Parkinson disease. *Acta Neuropathologica*, **2008**, 116, 25-35	14.3	76
62	MR imaging of brainstem atrophy in progressive supranuclear palsy. *Journal of Neurology*, **2008**, 255, 37-44	5.5	39
61	The genetics of frontotemporal dementia. *Neurologic Clinics*, **2007**, 25, 697-715, vi	4.5	13
60	Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson disease. *Movement Disorders*, **2007**, 22, 284	7	2
59	ELAVL4, PARK10, and the Celts. *Movement Disorders*, **2007**, 22, 585-7	7	19
58	Frontotemporal dementia and Parkinsonism linked to chromosome 17 with the N279K tau mutation. *Neuropathology*, **2007**, 27, 73-80	2	18
57	Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. *Acta Neuropathologica*, **2007**, 114, 243-54	14.3	18
56	Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). *Parkinsonism and Related Disorders*, **2007**, 13, 230-9	3.6	45
55	PARK8 LRRK2 parkinsonism. *Current Neurology and Neuroscience Reports*, **2006**, 6, 287-94	6.6	18
54	Lrrk2 and Lewy body disease. *Annals of Neurology*, **2006**, 59, 388-93	9.4	237
53	Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. *Archives of Neurology*, **2006**, 63, 1250-4		75

52	New and reliable MRI diagnosis for progressive supranuclear palsy. *Neurology*, **2006**, 66, 781; author reply 781	6.5	2
51	Brain acetylcholinesterase activity in FTDP-17 studied by PET. *Neurology*, **2006**, 66, 1276-7	6.5	15
50	Autosomal dominant dystonia-plus with cerebral calcifications. *Neurology*, **2006**, 67, 620-5	6.5	31
49	Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). *Orphanet Journal of Rare Diseases*, **2006**, 1, 30	4.2	79
48	Absence of rapid eye movement sleep behavior disorder in 11 members of the pallidopontonigral degeneration kindred. *Archives of Neurology*, **2006**, 63, 268-72		27
47	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson disease. *European Journal of Human Genetics*, **2006**, 14, 322-31	5.3	134
46	Hereditary diffuse leukoencephalopathy with spheroids: clinical, pathologic and genetic studies of a new kindred. *Acta Neuropathologica*, **2006**, 111, 300-11	14.3	76
45	Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. *American Journal of Human Genetics*, **2005**, 76, 672-80	11	453
44	Heredofamilial brain calcinosis syndrome. *Mayo Clinic Proceedings*, **2005**, 80, 641-51	6.4	65
43	The effect of tau genotype on clinical features in FTDP-17. *Parkinsonism and Related Disorders*, **2005**, 11, 205-8	3.6	27
42	PET in LRRK2 mutations: comparison to sporadic Parkinson disease and evidence for presymptomatic compensation. *Brain*, **2005**, 128, 2777-85	11.2	208
41	Severe vascular disturbance in a case of familial brain calcinosis. *Acta Neuropathologica*, **2005**, 109, 643-53	14.3	54
40	Lrrk2 pathogenic substitutions in Parkinson disease. *Neurogenetics*, **2005**, 6, 171-7	3	207
39	Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron*, **2004**, 44, 601-7	13.9	2228
38	Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. *Neurology* , **2004**, 62, 1619-22	6.5	217
37	Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). *Neurology*, **2004**, 63, 2165-7	6.5	101
36	Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. *Neurology*, **2003**, 60, 1766-9	6.5	104
35	Early and pre-symptomatic neuropsychological dysfunction in the PPND family with the N279K tau mutation. *Parkinsonism and Related Disorders*, **2003**, 9, 265-70	3.6	27

34	Hereditary tauopathies and parkinsonism. *Advances in Neurology*, **2003**, 91, 153-63		21
33	Japanese family with parkinsonism, depression, weight loss, and central hypoventilation. *Neurology*, **2002**, 58, 1025-30	6.5	26
32	Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family. *Archives of Neurology*, **2002**, 59, 943-50		32
31	Neuropathology of two members of a German-American kindred (Family C) with late onset parkinsonism. *Acta Neuropathologica*, **2002**, 103, 344-50	14.3	11
30	Clinical and genetic studies of families with the tau N279K mutation (FTDP-17). *Neurology*, **2002**, 59, 1791-3	6.5	43
29	SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. *Neurology*, **2002**, 59, 1625-7	6.5	103
28	Magnetic Resonance Imaging and Deep Brain Stimulation. *Neurosurgery*, **2002**, 51, 1423-1431	3.2	24
27	Physiologic assessment of autonomic dysfunction in pallidopontonigral degeneration with N279K mutation in the tau gene on chromosome 17. *Autonomic Neuroscience: Basic and Clinical*, **2002**, 102, 71-7	2.4	13
26	Interest in genetic testing in pallido-ponto-nigral degeneration (PPND): a family with frontotemporal dementia with Parkinsonism linked to chromosome 17. *European Journal of Neurology*, **2001**, 8, 179-83	6	11
25	Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17): PPND family. A longitudinal videotape demonstration. *Movement Disorders*, **2001**, 16, 756-60	7	8
24	Phenotypic correlations in FTDP-17. *Neurobiology of Aging*, **2001**, 22, 89-107	5.6	207
23	Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). *Parkinsonism and Related Disorders*, **2001**, 7, 81-88	3.6	24
22	Familial Parkinson's disease and related conditions. Clinical genetics. *Advances in Neurology*, **2001**, 86, 33-43		3
21	Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome. *Cancer*, **2000**, 88, 433-9	6.4	16
20	Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. *Annals of Neurology*, **1999**, 46, 374-81	9.4	82
19	Molecular genetics of familial parkinsonism. *Parkinsonism and Related Disorders*, **1999**, 5, 145-55	3.6	7
18	Rare and unusual parkinsonian syndromes. *Advances in Neurology*, **1999**, 80, 369-76		
17	A susceptibility locus for Parkinson's disease maps to chromosome 2p13. *Nature Genetics*, **1998**, 18, 262-5	36.3	436

16	Clinical neurophysiologic findings in patients with rapidly progressive familial parkinsonism and dementia with pallido-ponto-nigral degeneration. *Electroencephalography and Clinical Neurophysiology*, **1998**, 107, 213-22		21
15	The neuropathology of a chromosome 17-linked autosomal dominant parkinsonism and dementia ("pallido-ponto-nigral degeneration"). *Journal of Neuropathology and Experimental Neurology*, **1998**, 57, 588-601	3.1	114
14	Olfactory dysfunction in Parkinson's disease. *Clinical Neuroscience*, **1998**, 5, 94-101		5
13	Seizures after orthotopic liver transplantation. *Seizure: the Journal of the British Epilepsy Association* , **1997**, 6, 31-9	3.2	35
12	Rapidly progressive autosomal dominant Parkinsonism and dementia with Pallido-Ponto-Nigral Gegeneration (PPND) and Disinhibition-Dementia-Parkinsonism-Amyotrophy Complex (DDPAC) are clinically distinct conditions that are both linked to 17q21-22. *Parkinsonism and Related Disorders*, **1997**, 3, 67-76	3.6	11
11	German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia - Longitudinal observations. *Parkinsonism and Related Disorders*, **1997**, 3, 125-39	3.6	62
10	Complex partial status epilepticus after bone marrow transplantation for non-Hodgkin's lymphoma. *Bone Marrow Transplantation*, **1997**, 19, 637-8	4.4	6
9	Familial parkinsonism, dementia, and Lewy body disease: study of family G. *Annals of Neurology*, **1997**, 42, 638-43	9.4	46
8	Neuromuscular disorders in systemic malignancy and its treatment. *Muscle and Nerve*, **1996**, 19, 109-10	3.4	
7	Western Nebraska family (family D) with autosomal dominant parkinsonism. *Neurology*, **1995**, 45, 502-5	6.5	104
6	Familial parkinsonism: Our experience and review. *Parkinsonism and Related Disorders*, **1995**, 1, 35-46	3.6	39
5	Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. *Movement Disorders*, **1995**, 10, 650-7	7	59
4	Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. *Annals of Neurology*, **1992**, 32, 312-20	9.4	206
3	Genetic considerations in movement disorders. *Current Opinion in Neurology and Neurosurgery*, **1992**, 5, 324-30		2
2	Epileptiform electroencephalographic abnormalities in liver transplant recipients. *Annals of Neurology*, **1991**, 30, 37-41	9.4	32
1	Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17110-134		20